ASO Author Reflections: Long-Term Outcomes after Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases

Affiliations

Comment

Hallbera Gudmundsdottir et al. Ann Surg Oncol. 2023 Aug.

. 2023 Aug;30(8):4852-4853.

doi: 10.1245/s10434-023-13374-x. Epub 2023 Mar 20.

No abstract available

Comment on

Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.
Gudmundsdottir H, Habermann EB, Vierkant RA, Starlinger P, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Halfdanarson TR, Nagorney DM, Cleary SP. Gudmundsdottir H, et al. Ann Surg Oncol. 2023 Aug;30(8):4840-4851. doi: 10.1245/s10434-023-13372-z. Epub 2023 May 19. Ann Surg Oncol. 2023. PMID: 37208566 Free PMC article.

1. Gangi A, Howe JR. The landmark series: neuroendocrine tumor liver metastases. Ann Surg Oncol. 2020;27:3270–80. https://doi.org/10.1245/s10434-020-08787-x . - DOI - PubMed - PMC
1. Gudmundsdottir H, Habermann EB, Vierkant RA, et al. Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: Long-term follow-up of over 500 patients. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13372-z .
1. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. - DOI - PubMed
1. Partelli S, Bertani E, Bartolomei M, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163:761–7. - DOI - PubMed